Stock Analysis
Autonomix Medical, Inc. Common StockAMIX
Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
AnalystsStrong Buy8 analystsPrice is 0% of the way from the year's low to its high.
PMP Verdict
Weak fundamentals, expensive
Risks
- Valuation30
- Growth0
Weak fundamentals at a demanding price.
Market context
-2.9% today· Z 0.1σ
What's happening with AMIX
Profile
growth, profitability, earnings quality, moat and valuation lag behind.
How is each axis scored?
- Valuation30/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-132.3%)0/25
- P/S (n/a)10/25
- EV/EBIT (n/a)10/25
- Growth0/100 · Weak
- Revenue CAGR (n/a)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (n/a)0/25
- ROE (-509.4%)0/25
- Net margin (n/a)0/25
- Operating margin (n/a)0/25
- Financial Health53/100 · Moderate
- Altman Z (-24.77)3/25
- Current ratio (4.85)25/25
- Interest coverage (no interest expense)25/25
- Net cash / debt (n/a)0/25
- Quality0/100 · Weak
- Piotroski F (1/9)0/25
- Beneish M (n/a)0/25
- FCF conversion (n/a)0/25
- Margin stability (n/a)0/25
- Moat0/100 · Weak
- ROIC >12% years (n/a)0/25
- Median gross margin (n/a)0/25
- FCF-positive years (0/3 yrs)0/25
- Worst-year net margin (n/a)0/25
Risk Flags
- ⚠Altman Z -24.8 — distress-zone balance sheet
- ⚠5 loss-making years in recent history
About Autonomix Medical, Inc. Common Stock
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Show more
Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
Headquarters: THE WOODLANDS, TX · Employees: 11 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
30DP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-132.3%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 3Y history: -495.5%–-0.7% · lowest in history
P/S (TTM)—
Price / TTM Revenue (own statements)
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales—
Enterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio3.16xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-509.4%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-216.8%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin—
Net Income / Revenue
Operating Margin—
TTM EBIT / TTM Revenue
Gross Margin—
Gross Profit / Revenue
FCF Margin—
FCF / Revenue
True FCF Margin—
TTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR—
Compound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue—
TTM stock-based comp / TTM Revenue
Financial Health
53CAltman Z-Score-24.77D
Grade D: DistressBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio4.85xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio4.23xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage—
EBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.00xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
0EPiotroski F-Score1/9D
Grade D: WeakFinancial strength 0–9. >7 Strong
Beneish M-Score—
Earnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability—
EBIT margin std deviation. Lower = stable
Capex / Revenue—
TTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover—
Revenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 4 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Smith Trent N. Filed | Smith Trent N. | Grant / award | +15.0K | |
KLEMP WALTER V Filed | KLEMP WALTER V | Grant / award | +13.0K | |
Bisson Lori Filed | Bisson Lori | Grant / award | +13.0K | |
Hauser Bradley Filed | Hauser Bradley | Grant / award | +27.0K |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years—
Share of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)—
Median annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years0/3 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor—
Weakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$6.38
Cash & short-term investments per share (Finnhub)
Book Value / Share$5.83
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$3.46M
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$3.16M
Shareholders' equity (book value)
Asset / Liability4.87xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$10.00M
Current Market Capitalization
Beta-0.92B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Autonomix Medical, Inc. Common Stock (AMIX)
AMIX is down 2.90% at the last close. Autonomix Medical, Inc. Common Stock meets only 1 of 9 Piotroski F-Score criteria — a sign of weak underlying fundamentals. Altman Z-Score of -24.77 is below the 1.81 distress threshold — an elevated financial-risk flag.
- Autonomix Medical, Inc. Common Stock posted a net loss in 5 of 5 available completed fiscal years (2022–2026).
- At a valuation score of 30/100, AMIX trades at a premium to its historical multiples.
See how AMIX ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all AMIX moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 8 | Regular | 3.13 | -8.21% | -2.73 |
| Oct 8 | After-hours | 3.14 | -7.92% | -2.61 |
| Oct 5 | After-hours | 3.51 | -7.06% | -2.56 |
| Oct 2 | After-hours | 3.68 | -6.12% | -2.24 |
Frequently Asked Questions about AMIX
What is the current Autonomix Medical, Inc. Common Stock (AMIX) stock price?
AMIX is trading at $2.85 at the last market close, down 2.90% on the session. PreMarketPrice tracks AMIX pre-market, intraday and after-hours prices.
Is AMIX stock a buy right now?
PreMarketPrice's quantitative model rates Autonomix Medical, Inc. Common Stock's financial health at 53/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is AMIX stock overvalued?
Autonomix Medical, Inc. Common Stock trades at a trailing P/E of n/a and our valuation score rates it 30/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Autonomix Medical, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for AMIX. The Earnings section lists recent reports and updates as dates are announced.
What sector does Autonomix Medical, Inc. Common Stock operate in?
Autonomix Medical, Inc. Common Stock operates in the Healthcare sector, within the Surgical & Medical Instruments & Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does Autonomix Medical, Inc. Common Stock do?
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system.
About Autonomix Medical, Inc. Common Stock (AMIX) Stock
Autonomix Medical, Inc. Common Stock (AMIX) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry. As of the latest update, Autonomix Medical, Inc. Common Stock is trading at $2.85, down 2.90% on the day with a market capitalization of $10 million. The financial health score for AMIX is 53/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for AMIX stock.
AMIX Stock Analysis & Key Metrics
On PreMarketPrice, you can track Autonomix Medical, Inc. Common Stock (AMIX) across multiple dimensions:
- Pre-market price & movement: Real-time AMIX stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for AMIX with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Autonomix Medical, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 53/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for AMIX.
- Sector peers: Compare AMIX against 6 other healthcare stocks on key financial metrics.
Is AMIX a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Autonomix Medical, Inc. Common Stock (AMIX) as an investment. The financial health score of 53/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Autonomix Medical, Inc. Common Stock (AMIX) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.